On July 22, 2022 Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based technologies, reported that Dr. James A. Hayward, president and CEO of Applied DNA and its majority-owned biotherapeutics subsidiary, LineaRx Inc., will present data highlighting the advantages of its enzymatically produced linearDNA (linDNA) as an IVT template for mRNA production at the 2nd Annual mRNA-Based Therapeutics Summit on July 26-28, 2022, in Boston, Massachusetts (Press release, Applied DNA Sciences, JUL 22, 2022, View Source [SID1234616874]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Hayward’s presentation, titled ‘The Future of RNA Therapies Produced from LinearDNA Templates,’ is scheduled for Wednesday, July 27, at 4:30pm EST at Hilton Boston Logan Airport. A copy of the slide presentation will be made available to interested parties concurrent with the start of the presentation at View Source
LineaRx staff will be available at Booth 3 at the Summit. To schedule a meeting, contact: [email protected].
linDNA is an optimal IVT template for mRNA production as compared to plasmid DNA (pDNA). Produced by the LinearDNA platform, a cell-free enzymatic manufacturing platform for the large-scale production of high-fidelity DNA sequences for use in nucleic acid-based therapeutics, linDNA enables:
A simplified IVT workflow as compared to pDNA;
IVT from linDNA potentially requiring less DNA than IVT from pDNA to achieve equivalent RNA yields;
The production of difficult DNA sequences, such as precise poly(T) tails in IVT templates;
The removal of the problematic DNA sequences found in pDNA, such as antibiotic resistance genes; and,
Rapid scalability in a minimal footprint.
"Current IVT mRNA production methods must improve to move mRNA technology to broader commercialization to support therapeutic and vaccine development. As process yields and production scale have an impact on the manufacturing costs and consequentially on the cost per dose, we believe that linDNA’s numerous advantages over current pDNA as an IVT template can help solve many of the challenges currently experienced by mRNA developers and manufactures," stated Dr. Hayward.
Learn more about how linDNA can accelerate your DNA manufacturing through the clinic and towards commercialization: View Source